–News Direct–
Race Oncology Ltd (ASX:RAC) executive director Pete Smith speaks with Proactive alongside the companys recently appointed CEO – 25-year veteran of the biotech space, Dr Daniel Tillett. In this pivotal role, Dr Tillett will work closely with Dr Smith to steer the company's strategic, clinical and commercialisation efforts, with a primary focus on advancing bisantrene. Dr Tillett is already well acquainted with the cancer-targeting biotech firm. From September 2019 to March 2023, he served as Race's chief scientific officer and executive director, playing a crucial role in the company's growth and development. After this initial tenure, he continued to contribute to Race in a consultancy capacity.
My priority in stepping in as CEO is to ensure the clinical strategy we have for bisantrene is implemented and our promise to shareholders delivered. My belief in bisantrene and its commercial potential has never wavered," Dr Tillett said. We have an outstanding team at Race to execute on these opportunities and make a real difference for both patients and shareholders."
Contact Details
Proactive Investors
Gregg Castano
+1 203-762-5649
View source version on newsdirect.com: https://newsdirect.com/news/race-oncology-appoints-dr-daniel-tillett-as-ceo-483313601
Race Oncology Ltd
COMTEX_443911201/2655/2023-11-23T15:29:45
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Smart Herald journalist was involved in the writing and production of this article.